Video

PCa focal therapy: Who are the best candidates?

In this video, Scott Eggener, MD, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.

In this video, Scott Eggener, MD, of the University of Chicago, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.

 

More videos from Urology Times:

Study will test targeted PCa therapies based on genomic alterations

LUGPA President Dr. Richard Harris: 2020 challenges

Dr. Mara Holton discusses LUGPA's recent policy victories, upcoming challenges

Related Videos
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Study findings highlight gender gaps in oncology authorship and citation
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, answers a question during a Zoom video interview
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
1 expert in this video
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
1 expert in this video
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Related Content
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
May 30th 2025

PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology

Benjamin P. Saylor
The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
ORIC-944 shows promise in combination with AR inhibitors in mCRPC
May 30th 2025

ORIC-944 shows promise in combination with AR inhibitors in mCRPC

Hannah Clarke
Overall, 59% of patients achieved at least a 50% decline in PSA level.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Combination therapy linked to longer OS vs ADT in veterans with mHSPC
May 27th 2025

Combination therapy linked to longer OS vs ADT in veterans with mHSPC

Hannah Clarke
However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
May 21st 2025

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

Hannah Clarke
The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
© 2025 MJH Life Sciences

All rights reserved.